

WHAT IS CLAIMED IS

1. Transdermal drug delivery system (TDS) comprising
 - a cover which is impermeable for the active ingredient,
 - a matrix containing oxybutynin as active ingredient and
 - a facultative release liner, wherein the matrix further comprises
 - an Aloe Vera extract,
 - a pressure sensitive adhesive and
 - a cross linking agent for the adhesive.
2. Transdermal drug delivery system according to claim 1, comprising racemic oxybutynin, R-oxybutynin, S-oxybutynin or desethyl-oxybutynin.
3. Transdermal drug delivery according to claim 1, wherein the pressure sensitive adhesive of the matrix is comprised of an acrylate based polymer, preferably a polymer based on an acrylate-vinyl acetate copolymer.
4. Transdermal drug delivery system according to claim 1, wherein the matrix is comprised of Durotak 2287 or Durotak 2516.
5. Transdermal drug delivery system according to claim 1, wherein the matrix comprises Ti-acetylacetonate, Al-acetylacetonate or polybutyl-titanate as crosslinking agent.
6. Transdermal drug delivery system according to claim 1, wherein the extracting agent of the Aloe Vera-extract is a vegetable oil, preferably soybean oil.
7. Transdermal drug delivery system according to claim 6, wherein the Aloe Vera-extract comprises 5 to 15% by weight of Aloe Vera oil and 95 to 85% by weight of vegetable oil.

8. Transdermal drug delivery system according to claim 1, wherein the matrix comprises the Aloe Vera-extract as the only enhancer.

9. Transdermal drug delivery system according to claim 1, wherein the matrix comprises 5 to 40, preferably 10 to 35 and especially 15 to 30% by weight of oxybutynin (based on the matrix).

10. Transdermal drug delivery system according to claim 1, wherein the matrix comprises 10 to 25, preferably 12 to 20 and especially 14 to 18% by weight of Aloe Vera-extract (based on the matrix).

11. Transdermal drug delivery system according to claim 1, wherein the matrix comprises 0.1 to 5.0, preferably 0.3 to 3 and especially 0.5 to 2.0% by weight of the crosslinking agent (based on the matrix).

12. Transdermal drug delivery system according to claim 1, wherein the system has a surface of 5 to 80, preferably 10 to 60 and especially 20 to 50 cm².